"The Aaron Diamond AIDS Research Center (ADARC), one of the world's largest private research center dedicated exclusively to advancing the understanding, treatment, and prevention of HIV/AIDS, joined Columbia University Irving Medical Center (CUIMC) on January 1, 2020. Dr. David Ho remains the Center’s Director and was appointed the Clyde ’56 and Helen Wu Professor of Medicine at Columbia University. He leads an expanded and diverse ADARC faculty."

During the past decade, The Aaron Diamond AIDS Research Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Aaron Diamond AIDS Research Center" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 5 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "Rockefeller University" with 1 trials sponsored and "The Chemo-Sero-Therapeutic Research Institute" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Aaron Diamond AIDS Research Center" #1 collaborator was "AIDS Clinical Trials Group" with 2 trials as a collaborator, "Acute Infection and Early Disease Research Program" with 2 trials as a collaborator, "Glaxo Wellcome" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "The Aaron Diamond AIDS Research Center" are "HIV Infections" (9 trials), "HIV" (2 trials), "HIV-1 Infection" (2 trials) and "Acquired Immunodeficiency Syndrome" (1 trials). Many other conditions were trialed in "The Aaron Diamond AIDS Research Center" in a lesser frequency.

Most popular intervention types in "The Aaron Diamond AIDS Research Center" are "Drug" (7 trials), "Biological" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Stribild" (2 trials), "ALVAC(2)120(B,MN)GNP (vCP1452)" (1 trials), "Abacavir sulfate" (1 trials), "Amprenavir" (1 trials) and "Atazanavir" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Aaron Diamond AIDS Research Center" are 12 trials for "All" genders.

Currently, there are NaN active trials in "The Aaron Diamond AIDS Research Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in The Aaron Diamond AIDS Research Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in The Aaron Diamond AIDS Research Center, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".